Buy Potassium orotat tab. 500mg No. 20 Renewal

Description

Dosage form

Round, flat-cylindrical tablets of white color with a bevel, with a score on one side.

Structure

One tablet

Active substance:

Potassium orotate -500.0 mg

Excipients: lactose monohydrate - 165.0 mg, potato starch - 55.0 mg, povidone K-17 - 22.5 mg, calcium stearate - 7.5 mg.

Pharmacodynamics

The drug is a potassium salt of orotic acid.

Orotic acid is one of the precursors of pyrimidine nucleotides, which are part of nucleic acids, which are involved in the synthesis of protein molecules, and therefore salts of orotic acid are considered as substances of anabolic action and are used for disorders of protein metabolism to stimulate them.

Potassium orotate stimulates the synthesis of nucleic acids, the production of albumin in the liver, especially in conditions of prolonged hypoxia (oxygen deficiency), increases appetite, has diuretic (diuretic) and regenerative properties.

Pharmacokinetics

After oral administration, 10% of the dose taken orally is absorbed (absorbed) in the gastrointestinal tract.

In the liver, it is converted into orotidine-5-phosphate.

It is excreted by the kidneys (30% as metabolites).

Side effects

Potassium orotate is generally well tolerated.

In some cases, allergic skin reactions may occur, which disappear after interruption of treatment.

Potassium orotate can also cause mild indigestion (nausea, vomiting, diarrhea).

When used in high doses against the background of a low-protein diet, the development of liver dystrophy is possible.

If you experience side effects, consult your doctor.

Special conditions

During the period of treatment, it is desirable to follow a diet.

The effect of the drug on the ability to drive vehicles and mechanisms:

The drug does not cause drowsiness and a decrease in the speed of psychomotor reactions

Indications

- In complex therapy as an adjuvant: for diseases of the liver and biliary tract caused by acute and chronic intoxications (except for organic lesions of the liver and biliary tract)

- with the consequences of malnutrition in children (alimentary and alimentary-infectious malnutrition)

- during the period of recovery after illnesses

- with chronic physical stress.

Contraindications

Hypersensitivity to drug components

acute and chronic organic liver damage (including cirrhosis of the liver)

ascites (accumulation of fluid in the abdominal cavity)

urolithiasis disease

renal failure

children under 3 years old.

Carefully:

Pregnancy and lactation.

Drug interactions

Astringents and coating agents may slightly reduce the absorption of potassium orotate in the gastrointestinal tract.

Hinders the absorption of iron, tetracycline, sodium fluoride (the interval between taking the drug is at least 2-3 hours).

Oral contraceptives, diuretics, muscle relaxants, glucocorticoid drugs, insulin reduce the effect of the drug.

Dosage

Should be taken orally 1 hour before meals or 4 hours after meals.

Adults 250-500 mg 2-3 times a day.

The course of treatment lasts an average of 20-30 days.

If necessary, the treatment can be repeated after 1 month.

In exceptional cases, you can increase the dose of adults up to 3 g per day.

Children - 10-20 mg / kg of body weight per day, divided into 3-4 doses (for example, if the child's body weight is 25 kg, then the permitted dose is from 25 x 10 = 250 mg (1/2 tab.) To 25 x 20 = 500 mg (1 tablet per day, divided into 3-4 doses.) The course of treatment is 3-5 weeks.

If symptoms persist, consult your doctor.

Overdose

There are no data on overdose.

Storage conditions

Store at a temperature of 15 - 25 C out of the reach of children

Name ENG

POTASSIUM OROTATE

Clinical and pharmacological group

A drug that improves metabolism and energy supply of tissues

ATX code

orotic acid

Dosage

500mg

Structure

Per one tablet Active ingredient: Potassium orotate -500.0 mg Excipients: lactose monohydrate - 165.0 mg, potato starch - 55.0 mg, Povidone K-17 - 22.5 mg, calcium stearate - 7.5 mg.

Indications

In complex therapy as an adjuvant: for diseases of the liver and biliary tract caused by acute and chronic intoxications (with the exception of organic lesions of the liver and biliary tract) - with the consequences of malnutrition in children (alimentary and alimentary-infectious malnutrition) - during recovery after illness - with chronic physical stress.

Storage conditions and periods

In a dry place, at a temperature not exceeding 25 degrees, in the original packaging.

Expiration date: 4 years

INN / Active ingredient

potassium orotate

Contraindications

Hypersensitivity to drug components

acute and chronic organic liver damage (including cirrhosis of the liver)

ascites (accumulation of fluid in the abdominal cavity)

urolithiasis disease

renal failure

children under 3 years old.

Precautions: Pregnancy and lactation.

Pregnancy and lactation: With caution.

Specifications

Scope of the drug

Gastrointestinal tract

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

twenty

Scope of application

Hepatology

Minimum age from

3 years old

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Renewal

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Metabolic agent

Anatomical and therapeutic characteristics

A05BA Drugs for the treatment of liver diseases

Dosage form

Pills

The target audience

Adult

Dosage (volume) of the substance in the preparation

1 tablet contains: potassium orotate 500 mg

Expiration date in days

1460

Package weight, g

45